It has been reported that the addition of a DPP-4 inhibitor to patients with type 2 diabetes that is inadequately controlled by an α-glucosidase inhibitor achieved better glycemic control without further increasing the risk of weight gain and hypoglycemia [5]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.